### **Supplement**

# Supplementary Table 1 Item response rates as %, moderate and severe responses combined for the 11 items with the highest response rates

Item no.	Description	Severity score	Change	Mean
			score	
1	Appearance of purulent/thick sputum	59	59	59
3	Worsening of cough	69	61	65
5	Hard to cough out sputum	51	46	49
7	Colour of sputum changes	35	42	39
8	Increased volume of sputum	60	58	59
9	Abnormal sound during	52	45	49
	breathing/wheezing			
10	Laboured breathing	63	59	61
11	Shortness of breath	64	59	62
12	Chest distress	49	45	47
13	Limitation of activity	58	54	56
15	Exhaustion & fatigue	49	49	49

## Supplementary Table 2 Sensitivity and specificity using any 1 or more CERT item that scored moderate or severe

At least 1 positive CERT out of 5	'Exacerbating'	'Not exacerbating'	Total
CERT exacerbator	133	6	139
CERT non-exacerbator	1	13	11
Total	134	16	150

#### Notes:

Sensitivity 99.3, specificity 62.5%, kappa value 0.7161.

The heading 'Exacerbating' refers to patients with any 2 or more item combinations (out of the 10 final items) that scored moderate or severe in response to the severity of symptoms during an exacerbation.

**Supplementary Table 3** Sensitivity and specificity using any 2 or more CERT items that scored moderate or severe

CERT positive, at least 2 out of 5	'Exacerbating'	'Not exacerbating'	Total
CERT exacerbator	123	0	123
CERT non-exacerbator	1	16	27
Total	134	16	150

#### Notes:

Sensitivity 91.8, specificity 100%, kappa value 0.7046.

The heading 'Exacerbating' refers to patients with any 2 or more item combinations (out of the 10 final items) that scored moderate or severe in response to the severity of symptoms during an exacerbation.

### **Supplementary Table 4** Sensitivity and specificity using any 1 or more CERT item that scored moderate or severe

CERT positive, at least 1 out of 5	'Exacerbating'	'Not exacerbating'	Total
CERT exacerbator	121	18	139
CERT non-exacerbator	1	10	11
Total	122	28	150

#### Notes:

Sensitivity 99.2, specificity 36.0%, kappa value 0.4712.

The heading 'Exacerbating' refers to patients with any 3 or more item combinations (out of the 10 final items) that scored moderate or severe in response to the severity of symptoms during an exacerbation.

**Supplementary Table 5** Sensitivity and specificity using any 2 or more CERT items that scored moderate or severe

CERT positive, at least 2 out of 5	'Exacerbating'	'Not exacerbating'	Total
CERT exacerbator	120	3	123
CERT non-exacerbator	2	25	27
Total	122	28	150

#### Notes:

Sensitivity 98.4, specificity 89.3%, kappa value 0.8645.

The heading 'Exacerbating' refers to patients with any 3 or more item combinations (out of the 10 final items) that scored moderate or severe in response to the severity of symptoms during an exacerbation.

Supplementary Material: GlaxoSmithKline plc.-sponsored international advisory board

Scientific collaboration between GlaxoSmithKline plc. and diverse groups of experts (academia, industry, regulators, public health authorities, etc) is necessary to advance key medical/scientific discussions and to contribute and share GlaxoSmithKline plc.'s broad scientific knowledge and experience in various settings. GlaxoSmithKline plc.'s scientific engagement activities are entirely non-promotional and are designed to, in no way, influence the prescription, supply, sale, or use of their medicines. Any materials used (eg, slides, invitations, etc) are approved as non-promotional in the market in which the activity occurs and presentation of data is limited to that necessary to enable the discussion.

**Supplementary Figure S1** The CERT for use by Chinese patients, including pictograms, and an English translation



Tick ✓ the most accurate description for you today compared with your usual state

